Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalCCEL -0.84%58 Return-on-Tangible-Asset is 3.83% as of May. 2026, which is 38% above its 10-year median of 2.78. GuruFocus rates CCEL with a GF Score™ of 58/100 and a GF Value™ of $5.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 679 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 70.84% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cryo-Cell International's annualizedNet Income for the quarter that ended in May. 2026 was $2.22 Mil. Cryo-Cell International's average total tangible assets for the quarter that ended in May. 2026 was $58.01 Mil. Therefore, Cryo-Cell International's annualized Return-on-Tangible-Asset for the quarter that ended in May. 2026 was 3.83%.
The historical rank and industry rank for Cryo-Cell International's Return-on-Tangible-Asset or its related term are showing as below:
CCEL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -17.95 Med: 2.78 Max: 10.78
Current: -4.15
During the past 13 years, Cryo-Cell International's highest Return-on-Tangible-Asset was 10.78%. The lowest was -17.95%. And the median was 2.78%.
CCEL's Return-on-Tangible-Asset is ranked worse than 70.84% of 679
companies
in the Healthcare Providers & Services industry
Industry Median: 2.51
vs CCEL: -4.15
Cryo-Cell International (AMEX:CCEL) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Cryo-Cell International Return-on-Tangible-Asset Related Terms
Cryo-Cell International Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Cryo-Cell International's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International Return-on-Tangible-Asset Chart
CCEL vs EHSI, PIII, CCM: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (May. 2026) net income data.
What does a Return-on-Tangible-Asset of 3.83% mean?
Cryo-Cell International (CCEL) has a Return-on-Tangible-Asset of 3.83% as of May. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cryo-Cell International and its competitors. This is 38% above median its historical median of 2.78. According to the industry distribution chart, Cryo-Cell International ranks #481 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 70.8%.
Is Cryo-Cell International's Return-on-Tangible-Asset too high?
Cryo-Cell International's current Return-on-Tangible-Asset of 3.83% is 38% above median its 10-year median of 2.78. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.51. Cryo-Cell International's value of 3.83% is 52.6% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #481 out of 679 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Return-on-Tangible-Asset compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #481 out of 679 companies for Return-on-Tangible-Asset. This places Cryo-Cell International in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.51. Cryo-Cell International's value of 3.83% is 52.6% above this benchmark. While the company's 10-year median is 2.78 vs. the industry median of 2.51, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.51, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current Return-on-Tangible-Asset of 3.83% is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Return-on-Tangible-Asset is 3.83%, which is 38% above median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $5.45, compared to a current price of $3.53 — trading 35.2% below its estimated fair value. The current Return-on-Tangible-Asset is 3.83%, which is 38% above median its 10-year median of 2.78 and 52.6% above the Healthcare Providers & Services industry median of 2.51. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current Return-on-Tangible-Asset is 3.83% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (CCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of $3.53 is trading 35.2% below its estimated GF Value™ of $5.45.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for CCEL:
Return-on-Tangible-Asset: 3.83% (38% above median its 10-year median of 2.78)
GF Value™: $5.45 vs. price of $3.53 (35.2% below fair value)
Industry Position: 52.6% above the Healthcare Providers & Services median (#481 of 679)
No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for CCEL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCEL has been successfully added to your 
